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Abstract
Background: Acute kidney injury (AKI) refers to a broad spectrum of kidney damage and is attributed a high
morbidity and mortality rate at all degrees of severity. Obesity increases the risk for developing AKI. However, some
studies have shown that obesity at onset of AKI is paradoxically associated with greater survival. The aim of this
review is to explore the relationship between body mass index and survival in patients with AKI.
Methods: An electronic search will be conducted using MEDLINE, EMBASE, CINAHL and CENTRAL using predefined
search strategies. The cited and citing references of selected key studies will also be searched for relevant articles.
Risk of bias will be assessed using a modified Quality in Prognosis Studies (QUIPS) tool. The primary outcome will
be an exploration of the association between BMI and mortality in patients presenting with AKI. Two authors will
independently select, data extract, and risk of bias assess articles. Any discrepancies will be resolved by consensus
or by consulting a third author. A narrative synthesis of the findings from the included studies will be presented.
Meta-analyses will be conducted where the data is available from clinically and methodologically similar studies
and in the same format. Heterogeneity in such analyses, beyond that expected by chance, will be quantified using
the I2 statistic. Sub-group analyses will be performed to determine the influence of gender, AKI duration, underlying
aetiology, and intervening treatments, on pooled results.
Discussion: Body mass index may be an important modifiable risk factor for mortality in patients presenting with
AKI. The proposed systematic review will help to elucidate the association between all categories of BMI and
survival in this patient group.
Systematic review registration: PROSPERO CRD42017071124.
Keywords: Acute kidney injury, AKI, Body mass index, BMI, Mortality, Systematic review, Protocol
Background
Acute kidney injury (AKI) describes a rapid onset of kid-
ney function impairment, denoted by a significant drop
in renal function seen typically over a 48-h period. It is
characterised by an acute rise in serum creatinine and
reduction or absence of urine output. The term AKI
has replaced acute renal failure, for which there is no
standardised definition. It can be used to refer to a
broad spectrum of kidney damage and is attributed a
high morbidity and mortality rate at all degrees of se-
verity [1].
Conflicting evidence exists regarding the potential im-
pact of body mass index (BMI) on outcomes in patients
with AKI. Chao et al. (2014) showed a U-shaped associ-
ation between BMI and mortality in geriatric critically ill
AKI patients (for obese versus normal: [HR, 1.22, CI
1.01–1.49, p = 0.042]; for underweight versus normal
[HR, 1.60, CI 1.05–2.61, p = 0.038]), Danzinger et al.
(2016) showed that within-hospital mortality increased
with each 5 Kg/m2 increment in BMI (adjusted OR,
1.10, CI 1.06–1.24, p < 0.001), while Kim et al. (2017)
showed an inverse relationship with mortality (adjusted
HR, 0.94 [CI 0.90–0.98], p = 0.01) between patients in
the highest BMI tertile (25.5–37.1 Kg/m2) compared to
those in the lowest tertile (13.5–21.8 Kg/m2) [2–4]. The
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difference in these results might be explained by different
ethnic populations studied, highlighting the potential im-
pact of ethnicity and body composition on outcomes. The
paradoxical relationship shown in some studies between
obesity and survival has also been noted in patients with
CKD [5]. This is thought to be secondary to several factors
including a different metabolic profile compared to
healthy weight patients, greater lean body mass, and se-
questration of uraemic toxins in adipose tissue [6, 7].
The aim of this review is to explore the relationship
between BMI and survival in patients with AKI. To the
authors’ knowledge, there is currently no other system-
atic review published or planned which attempts to sum-
marise the evidence for whether body mass has a role in
determining mortality in this patient group. The precipi-
tating factors, aetiology and degrees of severity for AKI
are multifarious [8]. This, arguably, makes grouping of
studies difficult but as small decrements in kidney func-
tion are known to be of substantial clinical significance,
the incidence of all-cause mortality and its association
with body mass, despite the stage of AKI, will be the pri-
mary outcome of this review. It is hoped that in sum-
marising the current evidence, this systematic review
will inform practice and future trial design.
Objectives
The present systematic review will aim to assess whether
a similar obesity paradox exists in adult patients with AKI
as has been seen in patients with CKD. More specifically,
the review aims to answer the following research question:
In adult patients with AKI, is there an association between
BMI, at onset of AKI, and mortality?
Methods/design
Exposure
Adult studies that include BMI measurements for all
in-patients at presentation of AKI and mortality inci-
dence/risk will meet the exposure criteria.
Study design
Any design analysing longitudinal data. This will include
prognostic studies that, for example, have predicted risk
of mortality in patients with AKI based on presenting
characteristics, including BMI. Observational and
case-control studies which have recorded time-to-death
data, BMI and AKI occurrence (and ideally AKI stage)
will also be included.
Population
Adult in-patients (aged 18 years and above) with AKI.
Any study which includes a mix of ages (i.e. participants
are aged both < 18 years and above) but allows the ex-
traction of data specifically for participants > 18 years
will be included.
Outcome
Data, of any format, are provided on the association be-
tween BMI (measured upon presentation of AKI and
analysed as either a continuous variable or a categorical
variable) and mortality (incidence or risk).
Search methods for identification of studies
We will search the following databases for relevant stud-
ies with no language or date constraints: MEDLINE,
EMBASE, CINAHL and Cochrane Central Register of
Controlled Trials (CENTRAL).
The search strategy for all databases will combine free
text and where available index terms (e.g. MeSH). Key
search terms will include the following: (“acute kidney
injury” or “acute renal failure”) and (“body mass index”,
“BMI”, “obes*”, “*weight”) and (“mortality” or “survival”).
The aim of our search strategy is to yield adult studies
(age 18 and above) as well as studies of mixed ages that
allow the extraction of data for adult patients only.
Table 1 includes the index list for each database search
strategy and the time period covered by that database. It
is expected that a broad list of studies will be returned
so that all studies which include the data of interest for
this review can be found. The authors acknowledge that
MEDLINE defines the term “adult” as being aged
19 years or over. For this reason, the search terms
“18 year*” and “age* 18” will be searched in all fields (af )
and combined with “exp Adult/ or adult.mp”, where
“exp” denotes a search term that automatically includes
closely related indexing terms and “mp” describes a term
that appears in the title, abstract and subject heading.
The search strategies used by Kastner et al. (2006) when
reviewing the sensitivity of MEDLINE for extracting
age-specific studies were reviewed and informed the
strategy used in this MEDLINE search [9]. Similarly, the
Cinahl database search has been expanded to combine
the terms “((18 or eighteen) ADJ3 (age* OR year)).af”
with “adult.af” and “exp adult/”, to increase the sensitiv-
ity of the search. Here, “ADJ3” describes a search tech-
nique that finds terms in any order with two words (or
fewer) between them.
The cited and citing references of included studies that
meet the exposure criteria will be assessed to identify
further relevant articles that were not identified by the
aforementioned databases. Grey literature sources will
be searched for conference proceedings and relevant
study results. These will include “Copac”, “Google
Scholar”, “GreyNet International”, “OpenGrey” and “Pro-
quest Dissertations & Theses”.
Citation management and screening
Search results will be entered into Mendeley Reference
Manager package 2017 and duplicates will be removed.
Studies will be screened initially according to title and
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abstract by two authors independently, and those not
meeting the criteria will be discarded. Disagreements
will be resolved by discussion and referral to a third au-
thor if necessary.
After this initial stage, the full text of all remaining
studies will be reviewed by two authors independently
for inclusion or exclusion in the final study. As before,
disagreements will be resolved by discussion and referral
to a third author if necessary.
Table 1 Search strategy
Database Search strategy
EMBASE (1974 to present) 1. Acute kidney injury.mp. or acute kidney
failure/
2. body mass.mp. or body mass/
3. obesity/ or morbid obesity/
4. obesity.mp.
5. morbid obesity.mp.
6. sarcopenic obesity.mp. or sarcopenic obesity/
7. overweight.mp.
8. underweight.mp. or underweight/
9. body weight.mp. or body weight/
10. mortality/ or mortality.mp.
11. mortality rate/ or mortality rate.mp.
12. death rate.mp.
13. survival.mp. or survival/
14. survival rate.mp. or survival rate/
15. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
16. 10 or 11 or 12 or 13 or 14
17. 1 and 15 and 16
18. limit 17 to (adult < 18 to 64 years> or aged
< 65+ years>)
MEDLINE 1. Acute kidney injury.mp. or Acute Kidney
Injury/
2. acute renal failure.mp.
3. body mass index.mp. or Body Mass Index/
4. Body Weight/ or body mass.mp.
5. overweight.mp. or Overweight/
6. underweight.mp. or Thinness/
7. Obesity/ or obesity.mp.
8. morbid obesity.mp. or Obesity, Morbid/
9. obese.mp.
10. mortality.mp. or Mortality/
11. mortality rate.mp.
12. death rate.mp.
13. Survival/ or survival.mp.
14. survival rate.mp. or Survival Rate/
15. 1 or 2
16. 3 or 4 or 5 or 6 or 7 or 8 or 9
17. 10 or 11 or 12 or 13 or 14
18. 15 and 16 and 17
19. exp. Adult/ or adult.mp.
20. ((year* or age*) adj2 eighteen).af.
21. “18 year* .af.”
22. “age* 18 .af.”
23. 19 or 20 or 21 or 22
24. 18 and 23
CINAHL 1. (“acute kidney injur*”).ti,ab
2. (“acute renal failure”).ti,ab
3. “KIDNEY FAILURE, ACUTE”/
4. (1 OR 2 OR 3)
Table 1 Search strategy (Continued)
Database Search strategy
5. (“body mass index”).ti,ab
6. (BMI).ti,ab
7. (“body mass”).ti,ab
8. (obesity).ti,ab
9. (obese).ti,ab
10. (overweight).ti,ab
11. (underweight).ti,ab
12. (thin*).ti,ab
13. (weight).ti,ab
14. “BODY WEIGHT CHANGES”/
15. “BODY WEIGHT”/
16. “BODY MASS INDEX”/
17. “OBESITY, MORBID”/
18. OBESITY/
19. THINNESS/
20. (5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12
OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19)
21. (mortality).ti,ab
22. (survival).ti,ab
23. MORTALITY/
24. “HOSPITAL MORTALITY”/
25. (21 OR 22 OR 23 OR 24)
26. (4 AND 20 AND 25)
27. (adult).af
28. exp ADULT/
29. ((18 OR eighteen) ADJ3 (age* OR year*)).af
30. (27 OR 28 OR 29)
31. (20 AND 25 AND 26 AND 30)
Cochrane Central Register of
Controlled Trials (CENTRAL)
Acute kidney injury: ti,ab,kw
Acute kidney failure: ti,ab,kw
“acute renal failure”: ti,ab,kw
MeSH descriptor: [acute kidney injury] noexp.
#1 OR #2 OR #3 OR #4
Body mass index: ti,ab,kw
Body weight: ti,ab,kw
MeSH descriptor: [Body mass index] exp.
MeSH descriptor: [Body weight] noexp.
#6 OR #7 OR #8 OR #9
#5 AND #10
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Data extraction
Data extraction will be performed independently and in
duplicate by two review authors. Predefined data extrac-
tion spreadsheets will be used to cumulatively extract
study details and compile study data for each individual
study (Additional file 1). Pilot extraction of data will be
performed on three studies.
The information we record from all studies will in-
clude journal citation, study design, the type and setting
of the study, patient characteristics, number of partici-
pants, AKI diagnostic standard, AKI staging, and BMI
categorising ranges or whether BMI is reported as con-
tinuous or binary values. The type of modelling or statis-
tical approach will be recorded—for example, hazard
ratios (HR), odds ratio (OR), regression coefficients,
standardised beta regression coefficients, and standar-
dised mean differences—and any adjustment factors
used.
For interventional studies, we will record information
on the nature of the intervention(s) in each group (includ-
ing the treatment of the AKI) and mortality outcome.
Prognostic model studies will be analysed separately,
looking at model construction, internal validation and
external validation. It is anticipated that such studies do
not exist.
In the absence of any models, the ideal would be stud-
ies within an individual severity of AKI looking at BMI
and its association with mortality or a study covering
multiple stages of AKI with an association between BMI
and mortality described at every stage; stage of disease is
accounted for in other factors and BMI is adjusted by
stage of disease.
Efforts will be made to contact the authors of primary
studies to provide missing data where necessary. If a re-
sponse is not obtained within 4 weeks, a follow-up email
will be sent with a response awaited within 2 weeks. We
will not chase beyond that.
Assessment of risk of bias
It is not expected that any prognostic model studies will
be identified. In the event that such a study is found, the
Checklist for critical Appraisal and data extraction for
systematic Reviews of prediction Modelling Studies
(CHARMS) tool will be used to appraise for quality and
risk of bias [10].
For all other studies, data will be treated as observa-
tional and risk of bias will be assessed through use of
the QUIPS (QUality In Prognosis Studies) tool. This is a
prognostic risk of bias tool and has been adapted to suit
the requirements of this review (Additional file 2) [11].
This tool specifically considers confounding factors like
intervention and underlying clinical condition. It has six
domains:
1. Study participation
2. Study attrition
3. Prognostic factor measurement
4. Outcome measurement
5. Study confounding
6. Statistical analysis and reporting.
For each domain, specific guidance is given on how to
rate the adequacy of reporting by a study as yes, partial
or no. We will assign a judgement regarding the risk of
bias as high, moderate or low. The QUIPS spreadsheet
will be used for entry of risk of bias assessments. Two
review authors will independently complete the QUIPS
assessment for each study.
We will attempt to contact the trial corresponding au-
thor for clarification when insufficient detail is reported
to assess risk of bias. Once we have consensus on the
quality assessment of the six domains for eligible studies,
we will assign them to the following categories:
Low risk of bias: describes studies for which all do-
mains are scored as “yes”.
Moderate risk of bias: describes studies for which one
or more domains are scored as partly or one domain is
scored as “no”.
High risk of bias: describes studies for which more
than one domain is scored as “no”.
The rating of the overall quality of the evidence from
this review will be undertaken in consideration of
current guidance on the use of the GRADE (Grading of
Recommendations, Assessment, Development and Eval-
uations) approach applied to prognostic studies [12].
The quality and bias risk of included studies will be in-
dependently assessed by two authors and verified by a
third if necessary.
Strategy for data synthesis
We will provide a narrative synthesis of the findings
from the included studies.
Study authors will be contacted to ideally obtain the raw
data of studies reporting on BMI and mortality for pa-
tients with AKI. It is hoped this may allow the authors to
reclassify the data according to BMI categories (specific to
ethnic origin) and mortality risk within that category for
each AKI stage.
BMI will be categorised according to the World Health
Organisation criteria (underweight: BMI ≤ 19.9 Kg/m2;
normal weight: 20.0–24.9 Kg/m2; overweight: 25.0–
29.9 kg/m2 of BMI; obese I: 30.0–34.9 kg/m2 of BMI;
obese II: 35–39.9 Kg/m2 of BMI; obese III: BMI ≥ 40 Kg/
m2) or Asian criteria (underweight: BMI ≤ 18.5 Kg/m2;
normal weight: 18.5–22.9 Kg/m2; overweight: 23.0–
24.9 kg/m2 of BMI; obese I: 25.0–29.9 Kg/m2 of BMI;
obese II: BMI ≥ 30 Kg/m2), dependent upon the ethnicity
of the study population [13, 14]. We will use the
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generalised least-squares method for trend estimation to
calculate the risk of mortality associated with every 5 kg/
m2 increase in BMI [15, 16].
Where raw data is not available, similar studies will be
grouped together. For example, studies will be grouped by
in-patient populations (e.g. critically ill vs non-critically ill),
AKI staging/ definition (for example, as defined by the Kid-
ney Disease: Improving Global Outcomes [KDIGO] cri-
teria), and by the types of data available (such as hazard
ratios [HR], relative risks [RR] and odds ratio [OR]). Cat-
egorical and continuous BMI data will be analysed separ-
ately (as described above). Studies which report BMI data
as binary thresholds or categories will be grouped and used
to inform the narrative synthesis.
In order to maximise data for any further analyses,
we will consider whether data reported for each
study will allow for the calculation of alternate mea-
sures, e.g. unadjusted RR and/or ORs from raw data
for approximations of unadjusted HRs and associated
uncertainty [17, 18]. Any standardised beta regres-
sion coefficients from regression models will be con-
verted to odds ratios. Follow-up time over which
mortality is reported will be a consideration, particu-
larly when grouping time-to-event data.
The potential for meta-analysis within groups for each
type of data will be assessed by considering the meth-
odological (including risk of bias) and clinical similarity
of studies. Where meta-analysis is deemed appropriate,
the random effects model will be employed due to the
likely between study variations. Unadjusted and adjusted
data for the same outcome and metric (e.g. HR, OR) will
be analysed separately.
Heterogeneity in any meta-analyses will be quantified
using the I2 statistic to indicate variation beyond that ex-
pected from chance alone [19]. The I2 statistic has been
chosen in preference to Cochran’s Q as we anticipate a
small number of studies will be included in this analysis.
Interpretation of heterogeneity will not simply apply a
threshold judgement based on the percentage value of I2,
but will also consider strength of evidence for the hetero-
geneity (confidence interval, chi-squared test and/or p
value) and the size and direction of effect in the analysis
[10]. The level of heterogeneity will be interpreted as fol-
lows: 0–40% (small), 30–60% (moderate), 50–90% (sub-
stantial), 75–100% (considerable) [19]. If there is
substantial unaccounted heterogeneity, a meta-regression
analysis will be performed.
If there are 10 or more studies included in any given
meta-analysis, the potential for publication bias will be
assessed by funnel plot analysis [19].
Where clinical methodological heterogeneity prevents
appropriate meta-analysis of data, forest plots may be
used without a summary estimate to indicate the data
across studies.
Sub-group and sensitivity analysis
Sub-group analysis will be performed to determine the
impact of the following: gender, underlying aetiology, and
intervening treatments (for example, renal replacement
therapy V no renal replacement therapy). When perform-
ing the analysis for underlying aetiology, we will group
participants according to the precipitating cause of the
AKI: pre-renal, intra-renal or post-renal. Pre-renal injuries
describe an obstruction of blood flow to the kidneys. This
category might include surgical patients who likely experi-
enced hypovolaemia, participants presenting with dehy-
dration or cardiovascular participants. Intra-renal injuries
describe intrinsic damage to the kidneys, and this category
might include patients diagnosed with acute tubular ne-
crosis or whose underlying cause involved an autoimmune
condition such as Good pastures syndrome. Post-renal in-
juries describe an obstruction of urine from the kidneys
and might include patients requiring urological interven-
tion such as a nephrostomy. The information used to de-
termine the sub-group category of the underlying
aetiology will be obtained from characteristic data in-
cluded in the study description or from the raw data pro-
vided by the authors.
Meta-regression may be performed to explore the size
of the effect exerted by individual study variables as
identified by the risk of bias and quality assessments.
This may include the age of the participants, AKI dur-
ation and the duration of follow-up. Meta-regression will
not be performed if there are fewer than 10 studies in a
meta-analysis [19].
If there is moderate or greater quantified statistical
heterogeneity in a meta-analysis and debate had previ-
ously arisen about the inclusion of all the studies, we will
explore our decision-making process by removing the
studies which were the source of debate. The effect of
this sensitivity analysis will be reported and discussed.
In any meta-analysis performed, studies deemed at
high risk of bias (judged by either the QUIPS or
CHARMS method) will be excluded and the effect of
this will be evaluated in a sensitivity analysis.
Standards
Reporting will conform to Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) stan-
dards (see Additional file 3).
Discussion
Body mass index may be an important modifiable risk
factor for mortality in patients presenting with AKI.
Achieving an adequate nutritional intake in sufferers
with AKI is hypothesised to reduce length of stay and
improve rehabilitation potential by preventing or redu-
cing muscle wastage [20, 21]. However, the proposed
benefits of body compositional preservation have never
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been studied. By not understanding what change in body
composition is desirable for patients (depending on their
presenting body composition profiles or body mass indi-
ces), renal dietitians and medical teams cannot set
patient-specific nutritional goals that knowingly improve
outcomes.
This proposed systematic review will help to elucidate
the association between BMI and survival in patients
with AKI. Differences in patient characteristics—includ-
ing underlying cause of AKI; existing co-morbidities;
AKI definition, severity and treatment; ethnicity; and dif-
ferences in lean body mass profiles—are expected limita-
tions of this review. The authors intend to record these
characteristics and identify, where available, the factors
which might influence the relationship between BMI
and survival. This study also aims to highlight the het-
erogeneous nature of an AKI and the dangers in general-
ising results for all patients with an AKI.
Additional files
Additional file 1: Data Extraction Form 1—study characteristics.
(DOCX 17 kb)
Additional file 2: Modified QUIPS tool. (DOCX 24 kb)
Additional file 3: Completed PRISMA-P checklist. (DOCX 34 kb)
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